国产多西他赛为主的联合化疗治疗转移性乳腺癌临床疗效观察

目的观察国产多西他赛为主的联合化疗治疗转移性乳腺癌的疗效、不良反应和临床受益反应(Clinical benefit response,CBR),并以进口多西他赛作对照。方法A组30例转移性乳腺癌患者,既往未采用蒽环类药物治疗的14例采用国产多西他赛联合阿霉素治疗(A1组),既往蒽环类药物治疗失败的16例采用国产多西他赛联合卡培他滨治疗(A2组);B组25例转移性乳腺癌患者作对照,其中未采用蒽环类药物治疗的11例采用进口多西他赛联合阿霉素治疗(B1组),既往蒽环类药物治疗失败的14例采用进口多西他赛联合卡培他滨治疗(B2组);3周为1个周期,2周期评价疗效,记录不良反应。结果A组有效率(CR+PR)66.7%,肿瘤控制率(CR+PR+SD)93.3%。不良反应主要为骨髓抑制和脱发,可耐受,无治疗相关性死亡。CBR评价有效者73.3%;B组有效率68%,肿瘤控制率92%。不良反应与A组相似。CBR评价有效者72%。结论国产多西他赛为主的联合化疗治疗转移性乳腺癌有较好的疗效,不良反应可耐受,临床受益反应良好,与进口多西他赛的疗效和不良反应相似。

China Made of Docetaxel-based Combination Chemotherepy in Metastatic Breast Cancer Clinical Observation

Objective To observe the domestic Docetaxel mainly combination chemotherapy treatment of metastatic breast cancer therapeutic effect, clinical benefit and clinical response,and contrast with import Docetaxel. Methods A group of 30 cases of patients with metastatic breast cancer, adopt anthracycline-based medication 14 cases of domestic Docetaxel joint adriamycin （A1）, drug therapy failed anthracycline-based 16 cases with domestic Docetaxel joint capecitabine （A2）, Group B in 25 patients with metastatic breast cancer patients, including drugs without using anthracycline-based 11 cases imported Docetaxel more than the combined with adriamycin treatment （B1）, drug therapy failed anthracycline-based 14 cases imported Docetaxel more than combined capecitabine （B2）, Three weeks for a cycle, 2 cycle therapeutic evaluation, records of adverse reaction. Results A group of efficient （CR ＋ PR） 66.7%, tumor control （CR ＋ PR ＋ SD） 93.3%. Mainly for the adverse reaction, can inhibit bone loss and tolerance, no treatment-related deaths. CBR evaluation：effective 73.3% ;Group B 68% respectively, tumor control 92%. With A group of similar adverse reaction. CBR evaluation：effective 72%. Conclusion The domestic Docetaxel mainly combination chemotherapy treatment of metastatic breast cancer has good curative effect, adverse reaction can be tolerated, clinical benefit, and more and curative effect of import Docetaxel adverse reaction similar.